Dorys Lopez-Ramos

Medicine · Health Sciences

7h-index1.1kcitations36works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(27), Immunotherapy and Immune Responses(16), Adenosine and Purinergic Signaling(11), CAR-T cell therapy research(9), Mast cells and histamine(5)

Publications36 total

Abstract PO2-07-04: Applying the Alliance Trial Guidelines in Multi-focal Breast Disease Using an Artificial Intelligence Computational Platform: Economic Analysis and Cosmetic Sensitivity
Cancer Research·2024
Abstract PO2-01-01: Biophysical simulation using DCE-MRI to forecast response to NAT in HER2+ patients, with glucose characterization and orthogonal validation using FDG-PET
Cancer Research·2024
Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer
Breast Cancer Research·2023· 13 citedOpen Access
Supplementary Figures 1-2 from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2023Open Access
Supplementary Figures 1-2 from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2023Open Access
Supplementary Table 1 from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2023Open Access
Supplementary Table 1 from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2023Open Access
Data from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2023Open Access
Data from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2023Open Access
Table S7 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Table S3 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Table S5 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Data from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Table S3 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Table S6 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Table S7 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Supplementary Methods from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Table S6 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Tables S1, S2, S4, S8, S9 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
Supplementary Methods from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Tobias Bald(28), Nicole Glodde(28), Michael Hölzel(28), Thomas Tüting(28), Jennifer Landsberg(24), Thomas Quast(20), Dirk Schadendorf(20), Jonathan L. Schmid‐Burgk(19), Bartomeu Bibiloni Ramis(19), Arabella Young(19), Shin Foong Ngiow(19), Daniel Nettersheim(19), Hubert Schorle(19), Georgina V. Long(19), Jason Madore(19), Richard A. Scolyer(19), Antoni Ribas(19), Mark J. Smyth(19), Paul C. Tumeh(19), Waldemar Kolanus(18)